25 April 2012 - KYTHERA Biopharmaceuticals Inc (KYTHERA) on Wednesday announced with Bayer the successful completion of two European Phase III clinical trials with ATX-101, an injectable drug designed for the reduction of unwanted fat under the chin.

In a top-line analysis of the trial data, ATX-101 was found to be well tolerated and met the pre-specified primary endpoints by demonstrating a statistically significant reduction of moderate to severe submental fat, when compared to a placebo, as assessed by: a five-point Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) (p